AEZS:potential 6-/10-bagger this year:If phase3 for Zoptrex shows succesfull results in April, share price of AEZS will be ++$20/share afterwarts (before FDA decision). This because of the Adam Feuerstein biotech oncology rule: The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps< $300M. https://www.google.be/amp/s/www.thestreet.com/amp/story/12696926/1/the-feuerstein-ratain-rule-update-still-perfect-predicting-small-cap-cancer-drug-failure.html?client=safari